Antibacterial-Resistant Pseudomonas aeruginosa: Clinical Impact and Complex Regulation of Chromosomally Encoded Resistance Mechanisms

By P. Lister, D. Wolter, N. Hanson. Clinical Microbiology Reviews, 2009

1,857 citations recorded by the source corpus.

Subfields: Epidemiology, Molecular Biology, Molecular Medicine

View Paper: https://www.semanticscholar.org/paper/450fdee08bf90f43caf55357af20881047db09dc

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. A. Croxatto
2. D. Livermore

In Molecular Biology

1. Bernd H. A. Rehm
2. S. Levy
3. R. Jackson
4. S. Ghods
5. M. Silby
6. M. F. Moradali

In Molecular Medicine

1. D. Livermore
2. Bernd H. A. Rehm
3. S. Levy
4. S. Ghods
5. A. Croxatto
6. M. F. Moradali
7. A. Alanis

Citations in the corpus

• Pseudomonas genomes: diverse and adaptable. (2011, background): “Pseudomonas aeruginosa infections are particularly challenging because of the organisms’ broad intrinsic antimicrobial resistance (Lister et al., 2009).”
• ESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics (2024, neutral): “P. aeruginosa is an opportunistic pathogen which possesses various intrinsic mechanisms of resistance, including barriers to drug permeability, a wide array of multidrug efflux pumps and a chromosomally encoded AmpC enzyme ( Pseudomonas -derived cephalosporinase (PDC)) 122 .”
• Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections (2019, background): “Seventythree of 81 (90%) XDR isolates in fact were found to belong to just 3 clones, which were those of the major international MDR/XDR high-risk clones: ST175 (62), ST111 (9), and ST235 (5, 10).”
• Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance. (2011, background): “These mechanisms usually involve complex combinations of reduced porin expression and upregulation of multiple efflux pumps and intrinsic b-lactamases (Lister et al., 2009; Wolter et al., 2009a; Tomas et al., 2010).”
• How to manage Pseudomonas aeruginosa infections (2018, background): “aeruginosa produces carbapenemases belonging to the Class A KPC or GES-2 types and MBL of Class B [21,22,29].”
• Pseudomonas aeruginosa Lifestyle: A Paradigm for Adaptation, Survival, and Persistence (2017, background): “Likewise, overproduction of other multidrug efflux pumps such as MexXY and MexCD-OprJ can occur via mutations in regulatory loci leading to unleashing gene expression and a greater resistance to a variety of antimicrobial agents (Lister et al., 2009; Figure 3).”